David Miller | VP of Strategic Communications
Curevo Vaccine

A former biotech analyst, David has 20+ years of experience with business strategy, communications, and business analysis focused on the biotechnology industry. He is the Vice President of Strategic Communications at privately-held Curevo Vaccine, responsible for the determination of both corporate and communications strategy. He led the investor relations and communications program at Angion (NASDAQ:ANGN), helping take the company public via a 2021 IPO and ending via a merger with Elicio Therapeutics (NASDAQ:ELTX) in 2023. He held a variety of roles at Alpine Immune Sciences (NASDAQ:ALPN), helping take the company public via a reverse merger in 2017. ALPN was acquired by Vertex for $4.9B in 2024. During his time at Alpine BioVentures, he was the portfolio manager for their public company investment fund and helped start multiple companies on the private equity side. He’s also been a software company CEO, college professor, and an advisor to multiple entrepreneurs across a variety of industries. David is an avid sailboat racer, skippering his sailboat One Life in races throughout the Pacific Northwest. David earned his degrees at Western Washington University.